New findings may provide a new tool for detection of malignant-stage ovarian cancer. Researchers found that positron emission tomography and computed tomography (PET/CT), which images both functional and anatomic alterations in the body, was useful for preoperative cancer imaging of ovarian masses when used with a radiotracer that is actively metabolized by cells as fuel. Physicians imaging patients suspected of having malignant tumors can see where cancerous cells are hypermetabolizing the tracer and accurately predict whether a mass is malignant, cancerous but stable, or benign.

“We found that PET/CT imaging with the radiotracer 18F-FDG gave us beneficial information about the ovarian cancer stage that helped gynecologists in their treatment planning,” said Dr. Majbritt Frost, a research technologist from Aalborg Hospital (Denmark) and lead author of the study. “This research is important because it gives gynecologists and oncologists the opportunity to provide these women the best possible course of treatment. We were also able to find additional tumors, resulting in patient referral to the appropriate medical specialist.”

This study was conducted to explore PET imaging with a radiotracer that combines a fluorine-based medical isotope with fluorodeoxyglucose (18F-FDG), which mimics glucose as a source of energy, to determine the malignancy of adnexal masses. These are lumps in the tissue of the adnexa, or connected structures of the uterus. Most typically, these masses affect the ovaries and fallopian tubes, but they can also develop within supporting tissues. PET imaging with 18F-FDG was able to ascertain whether lumps were malignant, because cancerous tissues are far more metabolically active than normal cells and this hyperactivity shows up as “hot spots” on PET scans.

For the purposes of this study, 104 patients with a mean age of 62 years presenting adnexal masses with the potential for ovarian cancer were imaged using PET/CT with the radiotracer 18F-FDG prior to surgery. Results of the scans were classified as either benign or malignant and were then compared to surgical findings. Early research revealed that 18F-FDG PET/CT imaging was able to detect successfully 84% of benign and malignant tumors for these patients.

The ability to detect ovarian cancer expands hybrid molecular imaging in the field of gynecology. Already molecular imaging is useful for the staging of cervical cancer, and continuing research may one day provide insights into the staging of endometrial and other cancers for women.

The study’s findings were presented at the SNM’s 58th annual meeting, held June 4-8, 2011, in San Antonio (TX, USA).

 

Guangzhou Jia Yu medical equipment Limited